- Vera HoffmanCEO
- Vera is an entrepreneur whose focus is transforming industries via novel technology. She has 20 years experience in executive and advisory roles with startups through Global 10 enterprises, in multiple industries and geographies. Vera identified opportunities, defined strategy, determined product-market fit, built and led teams, managed programs, and guided technical development. She has an honors degree in math and chemistry from the University of British Columbia and an MBA from Harvard Business School.
- Peter CaravanAssociate Professor, Harvard Medical School and Co-Director, Institute for Innovation in Imaging, Massachusetts General Hospital
- Peter is a world leader in MRI contrast agent development and applications, with 20 years industrial and academic experience. In industry he worked on the development of the FDA-approved blood pool agent Ablavar® (Gadofosveset), and was co-inventor of the thrombus-specific agent EP-2104R, the first molecular MR imaging probe to enter human clinical trials. Since 2007 Peter has led a molecular imaging lab at Massachusetts General Hospital focused on contrast agents and molecular probes to image fibrosis and thrombosis, as well as alternatives to GBCAs. He is co-inventor of RVP-001.
- Eric GaleAssistant Professor, Harvard Medical School / Massachusetts General Hospital
- Eric is a chemist with over 10 years experience in the synthesis and structural characterization organic and inorganic compounds. He is co-inventor of RVP-001 and was instrumental in the discovery of this contrast agent and its preclinical characterization. Eric has a PhD from the University of Georgia and was a NIH-funded Ruth L. Kirschstein National Research Service Award Scholar at the Massachusetts General Hospital.
Consultants / Virtual Team
- John AmedioChemistry, Manufacturing, and Controls
- John provides technical and regulatory CMC development strategy for biotechnology and pharmaceutical companies working to bring drugs to market. John has 28 years experience in the pharmaceutical industry: he has delivered profitable and patented pre-clinical through commercial manufacturing processes for drugs including Ablavar®, Arbaclofen, Zinapar™, Zibulin™, Zymafos™, Favipiravir, and multiple NCE’s including peptides and metal-based drugs. John has authored and reviewed CMC sections for numerous regulatory filings (IND, Amendments, Annual Updates, IMPD and NDA). John has a PhD in organic chemistry from the University of Delaware.
- Philip GrahamPharmaceutical Development
- Phil provides seasoned, solution-oriented leadership in pharmaceutical product development. Phil is currently SVP of Strategy and Program Management at Sojournix, and was previously responsible for program development, and product and program management at Concert Pharmaceuticals. Phil has directed the development of over a dozen drugs, including the MRI contrast agents Ablavar® and EP-2104R. Phil has a BS with honors from the University of Otago, New Zealand, and a PhD in Analytical Chemistry from the University of Massachusetts, Amherst.
- Christopher PaytonCFO
- Chris is an expert in finance and entrepreneurship, both of which he has taught at Harvard Business School. An author of over thirty Harvard Business School case studies, Chris has also served as a consultant and trainer to central banks, global financial institutions, and multinational corporations. Chris has served as a senior officer of five early-stage businesses and is an active advisor to founders and investors in the Boston area. Chris has a Bachelor of Mathematics from the University of Waterloo and an MBA from Harvard Business School.
- Scott Reeder MD PhD
- Scott is a Professor, Vice Chair of Research and Chief of MRI in the Department of Radiology at the University of Wisconsin, Madison. Scott’s many contributions to radiology include development of quantitative biomarkers in cardiovascular and body MR imaging. Scott is the Director of the UW Liver Imaging Research Program; 2017 Chair of the Safety Committee for the International Society for Magnetic Resonance in Medicine (ISMRM); a Fellow of the ISMRM; a Fellow of the the Society of Computed Body Tomography and Magnetic Resonance (SCBT/MR); and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
- Gregory Sorensen MD
- Greg is Executive Chairman of IMRIS, and former President and CEO of Siemens Healthcare North America. Previously he was a Professor at Harvard Medical School and Co-Director of the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital. A board-certified neuroradiologist, Greg’s scientific career focused on developing new imaging methods to understand cancer of the brain, stroke, and migraine. Greg is a member of the Scientific Council of the National Institutes of Biomedical Imaging and Bioengineering, past Chairman of the Board of the Medical Imaging Technology Alliance, and serves on the Board of Directors of Research!America.
- Michael Tweedle PhD
- Mike is a Professor, Stefanie Spielman Chair in Cancer Imaging in Radiology, and Director of the Wright Center Molecular Imaging Agents Laboratory at The Ohio State University. He previously held the positions of President, Lead Scientist, and Chief Executive of Bracco Research USA. Mike is a ground-breaking and prolific innovator in contrast media: he invented and led translational development of the first generation macrocyclic MRI agent ProHance®; X ray, Optical, and US agents; diagnostic imaging pharmaceuticals for nuclear medicine; and a radiotheranostic. In 1995 Mike was awarded the Harry Fischer Medal for Excellence in Contrast Media Research.